As pharmaceutical ingenuity hits new heights, ensuring that patients gain access to innovative medicines requires a unique combination of evidence generation and communication
Making treatment decisions is a tough choice for oncologists: a therapy might save or significantly extend one patient’s life but not deliver the desired outcome for another patient.
The COVID-19 pandemic has placed immense stress on healthcare provision, but the emergency may also make major advances in cancer treatment even more relevant – if studies can continue to i
The FDA has started a priority review of Bristol-Myers Squibb Opdivo in combination with cisplatin as a first-line therapy for advanced urothelial carcinoma (UC), setting
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio
